Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Personalized medicine for MDS

    ... MDS and anemia who have a low (<500 U/L) erythropoietin level as well as low transfusion requirement.  Most ...

    Research Review last updated 05/02/2016 - 9:44am.

  2. MEDALIST Trial

    ... ESA regimen must have been either recombinant human erythropoietin (rHu EPO) > 40,000 IU/wk for at least 8 doses or ... low chance of response to ESA base on endogenous serum erythropoietin level > 200 U/L for subjects not previously treated with ESAs ...

    Clinical Trial last updated 02/22/2017 - 11:42am.

  3. Thrombopoiesis-stimulating agents and myelodysplastic syndromes

    ... or lenalidomide . The recombinant human erythropoietin (rHuEPO) erythropoiesis-stimulating agents, epoetin and ...

    Research Article last updated 03/04/2015 - 10:20am.

  4. The Evaluation of iron overload through hepcidin level and its related factors in myelodysplastic syndromes.

    ... ferritin (SF), C-reactive protein (CRP), and erythropoietin were measured by routine standard laboratory assays. CD4+ ...

    Research Article last updated 05/14/2013 - 3:00pm.

  5. Revisiting use of growth factors in myelodysplastic syndromes

    ... colony-stimulating factor (G-CSF) and recombinant erythropoietin (EPO) has improved symptoms in MDS patients in addition to ...

    Research Article last updated 07/31/2012 - 12:57pm.

  6. Clinical use of erythropoietic stimulating agents in myelodysplastic syndromes

    ... symptoms. For more than 20 years, recombinant human erythropoietin has been available for clinical use, and it has been employed in an attempt to relieve MDS-related anemia. Erythropoietin-alpha, erythropoietin-beta, and more recently darbepoetin have ...

    Research Article last updated 10/31/2011 - 10:51am.

  7. Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions.

    ... . In non-del(5q) patients, lenalidomide enhances erythropoietin receptor signaling. Future directions include use of ...

    Research Article last updated 10/11/2011 - 5:58pm.

  8. Azacitidine in lower-risk myelodysplastic syndromes.

    ... data for azacitidine combination therapy with erythropoietin , granulocyte colony-stimulating factor, and valproic ...

    Research Article last updated 10/11/2011 - 5:58pm.

  9. Durable long-term responses in patients with myelodysplastic syndromes treated with lenalidomide.

    ... despite previous treatment with recombinant erythropoietin . One patient began lenalidomide therapy because of ...

    Research Article last updated 10/11/2011 - 5:58pm.

  10. Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes

    ... For more than 20 years erythropoietin (rHEPO) has largely been used to treat anemia in ...

    Research Article last updated 10/11/2011 - 5:58pm.